/Company Directory

/

Asset Brief

OncoSil (P-32)

OSL·OncoSil Medical·Locally advanced pancreatic adenocarcinoma (unresectable, non-metastatic)·Phase 2·NCT05466799·Primary completion: 26 Jan 2026

Plain-language Brief

The trial in plain terms

The disease: Locally advanced pancreatic adenocarcinoma (LAPC) refers to pancreatic cancer that has grown into nearby blood vessels or structures and cannot be surgically removed, but has not spread to distant organs. It sits between early-stage resectable disease and metastatic disease. Patients in this setting are typically treated with chemotherapy, sometimes combined with radiation, to control tumour growth. Median survival in this setting remains poor with standard-of-care chemotherapy (per published literature).
What the asset is trying to do: OncoSil consists of phosphorus-32 (P-32) radioactive microparticles that are implanted directly into the tumour using endoscopic ultrasound (EUS) guidance, a procedure that uses an internal camera and ultrasound probe to reach the pancreas. Once implanted, the particles deliver localised beta radiation to the tumour from within, aiming to limit radiation exposure to surrounding healthy tissue. This approach differs from external beam radiotherapy, which delivers radiation from outside the body and passes through intervening tissues.
What the trial is measuring, and why it matters: The TRIPP-FFX trial (NCT05466799) compares FOLFIRINOX chemotherapy alone against FOLFIRINOX plus OncoSil in patients with LAPC (per ClinicalTrials.gov NCT05466799). FOLFIRINOX is a multi-drug chemotherapy regimen commonly used in this setting. An ASX announcement dated 2026-06-08 stated that the trial met its co-primary endpoints, though specific endpoint definitions and result figures were not disclosed in the input data provided. Primary completion was registered as 2026-01-26 (per ClinicalTrials.gov NCT05466799).
Efficacy benchmarks in this setting: In the LAPC setting, FOLFIRINOX chemotherapy has been associated with a median overall survival of approximately 24 months in published randomised data, though figures vary across studies and patient populations (per Suker et al, Lancet Oncology 2016, which pooled data from multiple centres). For metastatic pancreatic cancer, FOLFIRINOX produced a median overall survival of 11.1 months versus 6.8 months for gemcitabine alone in the ACCORD 11/PRODIGE 4 trial (Conroy et al, NEJM 2011). These figures relate to approved regimens in related settings and are not statistically comparable to early-stage or single-arm data from any experimental device or drug.
Commercial context: OncoSil holds CE Mark approval in Europe and TGA approval in Australia for use in locally advanced pancreatic cancer (per ASX announcement 2026-05-19 and company regulatory designations on file). An ASX announcement dated 2026-06-08 stated that OncoSil is progressing a Humanitarian Device Exemption (HDE) application with the US Food and Drug Administration (FDA); the HDE pathway is a US regulatory route for devices intended to treat or diagnose diseases affecting fewer than 8,000 individuals per year in the United States (per FDA HDE guidance). OncoSil is the lead asset of OncoSil Medical (ASX: OSL). The OSPREY post-market global observational registry (NCT04493632) is actively recruiting with a target of 500 patients (per ClinicalTrials.gov NCT04493632), and an Italian post-marketing registry (NCT06399172) is not yet recruiting with a target of 50 patients (per ClinicalTrials.gov NCT06399172).

Sources for this brief (7)

FOLFIRINOX Versus OncoSil in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma (TRIPP-FFX) · ClinicalTrials.gov · accessed 15 June 2026
OSPREY Post-market Global Multicentre Observational Prospective Registry · ClinicalTrials.gov · accessed 15 June 2026
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy · ClinicalTrials.gov · accessed 15 June 2026
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer (ACCORD 11/PRODIGE 4) · New England Journal of Medicine · accessed 15 June 2026
FOLFIRINOX in locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis · Lancet Oncology · accessed 15 June 2026
Humanitarian Device Exemption (HDE) Program · US Food and Drug Administration · accessed 15 June 2026
OncoSil Medical ASX Announcements

Trial Design

Design summary

Phase: Phase 2
Design type: Randomised, controlled, open-label, multi-centre trial. Two-arm: FOLFIRINOX chemotherapy alone versus FOLFIRINOX plus OncoSil.
Primary endpoint: Co-primary endpoints [ TODO: fill in — specific endpoint definitions not provided in input data ]; ASX announcement (2026-06-08) states co-primary endpoints were met.
Key secondary endpoints: [ TODO: fill in — secondary endpoints not specified in input data ]
Enrolment target: 88 patients (per ClinicalTrials.gov NCT05466799)
Current enrolment status: Active, not recruiting (per ClinicalTrials.gov NCT05466799)
Sites: Multi-centre: Australia, United Kingdom, Spain, Italy, Belgium (per company notes on file)
Expected readout window: Primary completion was registered as 2026-01-26 (per ClinicalTrials.gov NCT05466799). An ASX announcement dated 2026-06-08 reported that the trial met its co-primary endpoints. An oral presentation of TRIPP-FFX data was accepted at ESMO GI 2026 (per ASX announcement 2026-06-09).

Asset Track Record

Did OSL deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

8 June 2026regulatory decisionFDA HDE approval decision for OncoSilhit · positivesrc
2 July 2026regulatory decisionFDA HDE final review completion and approval decisionhit · positivesrc ASX ↗
19 July 2026regulatory decisionOncoSil™ device Saudi FDA — OncoSil Medical Receives Saudi Arabia FDA Approvalhit · positivesrc ASX ↗
12 July 2026otherOncoSil Medical Completes Manufacturing Validationhitsrc ASX ↗
1 July 2026otherOncoSil Selected for Major European Pancreatic Cancer Studyhitsrc ASX ↗
8 June 2026regulatory decisionOncoSil™ FDA — OncoSil progresses HDE with US FDAhit · positivesrc ASX ↗
8 June 2026data readoutTRIPP-FFX Clinical Trial Meets Co-Primary Endpointshit · positivesrc ASX ↗
19 May 2026regulatory decisionOncoSil™ TGA — OncoSil Medical Receives TGA Approval in Australiahit · positivesrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for OncoSil (P-32) and peers

OncoSil (P-32)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for OncoSil (P-32). Showing past 6 months and next 12 months · 3 later hidden.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Trial design comparison

How OncoSil (P-32) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
OncoSil (P-32)	OncoSil Medical	Radioligand Other	Phase 21L	Randomised, controlled, open-label, multi-centre trial. Two-arm: FOLFIRINOX chemotherapy alone versus FOLFIRINOX plus OncoSil.	Co-primary endpoints [ TODO: fill in — specific endpoint definitions not provided in input data ]; ASX announcement (2026-06-08) states co-primary endpoints were met.	[ TODO: fill in ]	88 patients (per ClinicalTrials.gov NCT05466799)	88

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Small Molecule OtherASX peers ›

17 activeexpand ›

TU
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Phase 4
Tianjin Medical University Cancer Institute and Hospital·Recruiting·Primary completion 1 Apr 2026·NCT05035147
R
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for OncoSil (P-32) yet. Broker coverage of OncoSil Medical is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.

Asset Track Record

Did OSL deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

8 June 2026regulatory decisionFDA HDE approval decision for OncoSilhit · positivesrc
2 July 2026regulatory decisionFDA HDE final review completion and approval decisionhit · positivesrc ASX ↗
19 July 2026regulatory decisionOncoSil™ device Saudi FDA — OncoSil Medical Receives Saudi Arabia FDA Approvalhit · positivesrc ASX ↗
12 July 2026otherOncoSil Medical Completes Manufacturing Validationhitsrc ASX ↗
1 July 2026otherOncoSil Selected for Major European Pancreatic Cancer Studyhitsrc ASX ↗
8 June 2026regulatory decisionOncoSil™ FDA — OncoSil progresses HDE with US FDAhit · positivesrc ASX ↗
8 June 2026data readoutTRIPP-FFX Clinical Trial Meets Co-Primary Endpointshit · positivesrc ASX ↗
19 May 2026regulatory decisionOncoSil™ TGA — OncoSil Medical Receives TGA Approval in Australiahit · positivesrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for OncoSil (P-32) and peers

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Trial design comparison

How OncoSil (P-32) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
OncoSil (P-32)	OncoSil Medical	Radioligand Other	Phase 21L	Randomised, controlled, open-label, multi-centre trial. Two-arm: FOLFIRINOX chemotherapy alone versus FOLFIRINOX plus OncoSil.	Co-primary endpoints [ TODO: fill in — specific endpoint definitions not provided in input data ]; ASX announcement (2026-06-08) states co-primary endpoints were met.	[ TODO: fill in ]	88 patients (per ClinicalTrials.gov NCT05466799)	88

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Small Molecule OtherASX peers ›

17 activeexpand ›

TU
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Phase 4
Tianjin Medical University Cancer Institute and Hospital·Recruiting·Primary completion 1 Apr 2026·NCT05035147
R
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

OncoSil (P-32)n = 88

OncoSil Medical·Radioligand Other·Phase 2·1L

Design: Randomised, controlled, open-label, multi-centre trial. Two-arm: FOLFIRINOX chemotherapy alone versus FOLFIRINOX plus OncoSil.
Primary endpoint: Co-primary endpoints [ TODO: fill in — specific endpoint definitions not provided in input data ]; ASX announcement (2026-06-08) states co-primary endpoints were met.
Dosing: [ TODO: fill in ]
Eligibility: 88 patients (per ClinicalTrials.gov NCT05466799)

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancern = —

Tianjin Medical University Cancer Institute and Hospital·Small Molecule Other·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancern = —

Angiodynamics, Inc.·Surgical Device·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCn = —

RenovoRx·Small Molecule Other·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancern = —

Jiangsu Healthy Life Innovation Medical Technology Co., Ltd·Surgical Device·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)n = —

Innovent Biologics (Suzhou) Co. Ltd.·Monoclonal antibody·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancern = —

Quercis Pharma AG·Small Molecule Other·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutationsn = —

SWOG Cancer Research Network·Monoclonal antibody·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancern = —

NRG Oncology·Surgical Device·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPCn = —

Sahlgrenska University Hospital·Small Molecule Other·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.n = —

Assiut University·Small Molecule Other·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)n = —

Sun Yat-sen University·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancern = —

HonorHealth Research Institute·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Pre-operative Treatment for Patients With Untreated Pancreatic Cancern = —

HonorHealth Research Institute·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumoursn = —

AstraZeneca·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancern = —

OHSU Knight Cancer Institute·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDACn = —

GERCOR - Multidisciplinary Oncology Cooperative Group·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancern = —

National Cancer Institute (NCI)·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

NALIRIFOX as Induction Therapy in LAPCn = —

The First Affiliated Hospital with Nanjing Medical University·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoman = —

Asan Medical Center·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancern = —

Sun Yat-sen University·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancern = —

Tianjin Medical University Cancer Institute and Hospital·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancern = —

Akeso·Bispecific Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancern = —

Fudan University·Monoclonal antibody·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancern = —

Hebei Medical University Fourth Hospital·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)n = —

University of Kansas Medical Center·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancern = —

ImmunityBio, Inc.·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patientsn = —

Fudan University·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patientsn = —

Fudan University·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancern = —

Sun Yat-sen University·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoman = —

OncoSil Medical Limited·Surgical Device·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancern = —

Memorial Sloan Kettering Cancer Center·Surgical Device·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.n = —

Shanghai Zhongshan Hospital·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancern = —

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancern = —

Peking University Third Hospital·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancern = —

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDACn = —

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)n = —

Peking University Third Hospital·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Adebrelimab and Chidamide for Pancreatic Cancern = —

Liu Xiufeng·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancern = —

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·Monoclonal antibody·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancern = —

Shanghai Zhongshan Hospital·Monoclonal antibody·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACn = —

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·Bispecific Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancern = —

Peking University First Hospital·Monoclonal antibody·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancern = —

EXACT Therapeutics AS·Surgical Device·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancern = —

Fudan University·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.n = —

Allist Pharmaceuticals, Inc.·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Studyn = —

M.D. Anderson Cancer Center·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancern = —

West China Hospital·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancern = —

Peking Union Medical College Hospital·Monoclonal antibody·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapyn = —

Ruijin Hospital·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapyn = —

Ruijin Hospital·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

OtherASX peers ›

13 activeexpand ›

HR
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
Phase 2
HonorHealth Research Institute·Active, not recruiting·Primary completion 3 Mar 2024·NCT03138720
G-
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
Phase 2
GERCOR - Multidisciplinary Oncology Cooperative Group·Active, not recruiting·Primary completion 9 Dec 2024·NCT03806309
AC
mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Phase 2
Asan Medical Center·Active, not recruiting·Primary completion 23 Jan 2025·NCT04986930
HU
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Phase 2
Hebei Medical University Fourth Hospital·Recruiting·Primary completion 1 June 2025·NCT06435260
II
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Phase 2
ImmunityBio, Inc.·Active, not recruiting·Primary completion 13 Oct 2025·NCT04390399
FU
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Phase 2
Fudan University·Recruiting·Primary completion 1 Dec 2025·NCT06359275
SZ
AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
Phase 2
Shanghai Zhongshan Hospital·Not yet recruiting·Primary completion 9 Apr 2026·NCT07208539
PU
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
Phase 2
Peking University Third Hospital·Not yet recruiting·Primary completion 1 June 2026·NCT06422156
PU
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Phase 2
Peking University Third Hospital·Not yet recruiting·Primary completion 1 July 2026·NCT06009029
MA
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
Phase 2
M.D. Anderson Cancer Center·Active, not recruiting·Primary completion 6 Apr 2027·NCT04481204
WC
A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer
Phase 2
West China Hospital·Recruiting·Primary completion 15 Apr 2027·NCT07101679
RH
Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
Phase 2
Ruijin Hospital·Recruiting·Primary completion 1 Aug 2027·NCT07306286
RH
IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
Phase 2
Ruijin Hospital·Recruiting·Primary completion 1 Aug 2027·NCT07306273